Biocardia shares update from japan pmda consultation on cardiamp autologous cell therapy for ischemic heart failure; foreign data expected to be sufficient for product approval

Sunnyvale, calif., nov. 29, 2023 (globe newswire) -- biocardia, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update after its recent consultation with japan's pharmaceutical and medical device agency (pmda) towards approval of its cardiamp autologous cell therapy for the treatment of patients with ischemic heart failure of reduced ejection fraction (hfref).
BCDA Ratings Summary
BCDA Quant Ranking